Background
==========

Insulin gene (*INS*) mutations have recently been described as a common cause of permanent neonatal diabetes (PNDM) and a rare cause of diabetes diagnosed in childhood or adulthood \[[@B1]-[@B4]\]. Heterozygous mutations in *INS*account for 15 - 20% of cases of PNDM \[[@B4],[@B5]\]. Gene discovery can lead to recognition of novel phenotypes \[[@B6]\] and recognition of novel clinical subgroups. For example, MODY was initially clinically defined as autosomal dominantly inherited, non insulin dependent, early-onset diabetes, but now there are at least eight distinct genetic subgroups of MODY, most of which have a discrete phenotype and specialized treatment needs \[[@B6]\]. An R46Q *INS*mutation was recently described in a Norwegian study of 62 probands fulfilling conventional MODY criteria. In addition, they examined 223 patients from the population-based Norwegian Childhood Diabetes Registry and found an R55C *INS*mutation. One hundred blood donors were screened negative for these mutations \[[@B7]\]. The Italian study group on early onset diabetes has detected two *INS*mutations (A23S and G23S) in children negative for 5 type 1 diabetes (T1D) autoantibodies \[[@B1]\]. In addition, an R6C mutation was identified in an English MODY family and a L68M mutation was described in a family of Turkish origin with young-onset type 2 diabetes \[[@B3]\]. Furthermore, a recent screening for *INS*mutations in 252 patients diagnosed clinically with T1D between 6 months and 17 years of age identified 2 de novo heterozygous mutations G32S and R89C among the 25 (8%) antibody-negative patients \[[@B8]\]. To our knowledge, no studies have screened women with gestational diabetes mellitus (GDM) for *INS*mutation. GDM was defined as an abnormal glucose tolerance diagnosed for the first time in pregnancy.

We aimed to evaluate the prevalence and the disease-associated phenotype of *INS*mutations among diabetic patients diagnosed with MODY, anti-body negative T1D or GDM.

Methods
=======

*INS*was sequenced in 116 unrelated MODYX probands: 48 Danish, age at diagnosis (mean ± SD) 24 ± 19 years, BMI 24.8 ± 5.5 kg/m^2^, and 68 Czech, age at diagnosis 18 ± 8 years, BMI 22.6 ± 5.0 kg/m^2^, 83 Danish diabetic patients previously diagnosed with GDM, age at examination 40 ± 7 years, BMI at examination 28.1 ± 6.5 kg/m^2^, 34 GAD autoantibody-negative T1D patients, age at diagnosis 20 ± 16 years and 96 glucose tolerant control individuals, age at examination 46 ± 7 years, BMI 26.4 ± 4.4 kg/m^2^. All MODYX probands were from families fulfilling the conventional criteria of MODY \[[@B5]\] defined by: diabetes diagnosed before 25 years of age in at least one of the family members. No treatment with insulin and/or measurable C-peptide at least one year after diagnosis. Autosomal dominant inherited diabetes with known diabetes in at least two consecutive generations.

All MODY probands were screened negative for mutations in the MODY genes *HNF4A*, *GCK*and *HNF1A*. Women with GDM and all GAD autoantibody-negative T1D patients had a positive family history of diabetes including a diabetic parents and or child with diabetes. The control group was randomly selected from the population-based study Inter99 \[[@B9]\]. Additional family members of the probands with an *INS*mutation were examined and screened for the family-specific *INS*mutation. The participants and examined family members gave their informed written consent, and the study protocols were approved by the ethical committees. The genomic sequence of *INS*was analysed in two segments covering the two exons, exon-intron boundaries and UTRs. Sequencing analyses were performed as described \[[@B4]\]. Analyses of the *INS*sequence revealed four low-frequency (minor allele frequency = 0.05) and three frequent (minor allele frequency\>0.05) variants (Table [1](#T1){ref-type="table"}).

###### 

*INS*gene variants identified in MODY (*n*= 116), T1DM (*n*= 34), GDM (*n*= 83) and controls (*n*= 96)

  ---------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                     MAF (%)                          
  --------------- -------------------- ------------------------- ------------------ ---------------- ---------------- --------------- ---------------
  **rs number**   **SNP**              **Position on chr. 11**   **Part of gene**   **MODY**\        **T1D ab^-^**\   **GDM**\        **Controls**\
                                                                                    **(*n*= 116)**   **(*n*= 34)**    **(*n*= 83)**   **(*n*= 92)**

                                                                                                                                      

  Novel           c.-218A\>C           2.138.995                 5\'UTR             0.4              0                0               0

                                                                                                                                      

  rs689           c.-23A\>T            2.138.800                 Intron             27               10               33              28

                                                                                                                                      

  rs5505          c.-9C\>T             2.138.786                 5\'UTR             0.9              0                0.6             0^A^

                                                                                                                                      

  Novel           c.17G\>A, p.R6H      2.138.761                 Exon               0.4              0                0               0

                                                                                                                                      

  Novel           c.137 G\>A, p.R46Q   2.138.641                 Exon               0.4              0                0               0

                                                                                                                                      

  rs3842752       c.\*9C\>T            2.137.649                 3\'UTR             20               7                27              21

                                                                                                                                      

  rs3842753       c.\*22C\>A           2.137.636                 3\'UTR             26               10               34              28
  ---------------------------------------------------------------------------------------------------------------------------------------------------

SNP locations (-strand) are displayed counting from the first translated nucleotide in pre-proinsulin (*INS*). Base-pair positions are displayed counting from the p-arm telomere of chromosome 11 (according to the Base position feature in the Human (*Homo sapiens*) Genome Browser Gateway Human Mar. 2006 \[hg18\] assembly (<http://genome.ucsc.edu/cgi-bin/hgGateway>, assessed 19 June 2009). Minor allele frequencies (MAF) are given as a percentage.

^A)^Subsequent genotyping of 198 population-based individuals revealed a MAF of 0.7%

Control individuals were collected as a subset of the population based study Inter99 of middle-aged Danish individuals.

Results and Discussion
======================

One novel mutation c.17G\>A, R6H, was identified in *INS*in a Danish MODYX family (Figure [1A](#F1){ref-type="fig"}). The mutation is located in the signal peptide of proinsulin and was not present in 96 control individuals. The proband, M132-1, had been diagnosed at 20 years of age with mild diabetes treated with diet and oral hypoglycaemic agent (OHA). His 20-years-old son, M132-2, carried the mutation but had normal glucose tolerance. The brother of the proband, M132-4, carried the mutation and had been diagnosed with diabetes at 51 years of age. A daughter, M132-5, of the brother carried the mutation and had been diagnosed with IGT at the age of 26 and with GDM at the age of 27 years. Two carriers of *INS*R6H, M132-2 and M132-4, were also examined with an OGTT at age 15 years and 46 years, respectively. Interestingly, they both had a \~30% reduction in beta-cell function over a period of 5 years measured as insulinogenic index calculated from OGTT data (s-insulin 30 min (pmol/l) - s-insulin 0 min (pmol/l)/p-glucose 30 min (mmol/l). Insulinogenic index of M132-2 declined from 50 to 33 and for M132-4 from 19 to 13. BMI for M132-2 increased from 19.7 to 24.8 kg/m^2^; for M132-4 BMI was unchanged, 24.2 kg/m^2^, over the 5-year period. The R6 residue is conserved across mammalian species (rhesus monkey, elephant, mouse, dog and horse) and xenopus but is not conserved in lizard (S), platus (G) or stikleback (Q). A mutation in the same codon, R6C, was recently described in an English MODY family affecting the proband, the mother and the maternal grandmother \[[@B3]\], underlining a putative importance of this residue for proper function of the signal peptide.

![**Segregation of *INS*R6H (Figure 1A) and R46Q (Figure 1B) mutations in two MODY families**. Symbols denote the following: square, male; circle, female; empty symbol, normal glucose tolerant subject; filled symbol, diabetic person; quarter filled, impaired glucose tolerance status/gestational diabetes; symbol with arrowhead, proband. The text, under each individual represents the following: Subject id; age at examination (age at diagnosis); BMI (kg/m^2^); NGT, normal glucose tolerance; IGT, impaired glucose tolerance; GDM, gestational diabetes mellitus; DM, diabetes mellitus; treatment and mutation status; AAO, age of onset.](1471-2350-11-42-1){#F1}

In a Czech MODY proband a previously described R46Q mutation was found (Figure [1B](#F1){ref-type="fig"}). The mutation is located at residue 22 of the B chain. The mutation co-segregates with diabetes in two affected relatives and is not present in any of the non-diabetic family members or 96 controls. The proband, a 17-year old girl, was diagnosed with diabetes at 13 years of age and had been treated with insulin since onset of disease. Her mother was diagnosed at 14 years of age with polyuria and polydipsia, and had been treated with insulin since onset of diabetes. The grandmother was diagnosed with diabetes at 35 years of age and treated with OHA and insulin. No coding mutations were found in GDM women or GAD-negative type 1 diabetic patients.

It is very likely that the R46Q and R6H mutations are disease causing and not just rare neutral polymorphisms. In already published studies \[[@B1],[@B3],[@B7],[@B8]\] a total of 1560 individuals primarily of Northern European ancestry have been screened for *INS*mutations. The R46Q mutation was identified in one Norwegian MODY family \[[@B7]\]. The mutation segregated with diabetes in the family. The R6H mutation has not been identified in the 1560 examined individuals indicating that this mutation is not a rare polymorphism. Furthermore, we have screened additional 74 Danish individuals (data not shown) without identifying the R46Q and R6H mutations.

Conclusion
==========

Mutations in *INS*can be a rare cause of MODY and we conclude that screening for mutations in *INS*should be recommended in MODYX patients.
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GAD: Glutamic acid decarboxylase; GDM: Gestational diabetes mellitus; INS: Insulin gene; MODY: Maturity-onset diabetes of the young; PNDM: Permanent neonatal diabetes mellitus.
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